T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone781-761-4646
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.50 million
Profitability
Miscellaneous
Employees153
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable
T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions
What is T2 Biosystems' stock symbol?
T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."
How were T2 Biosystems' earnings last quarter?
T2 Biosystems Inc (NASDAQ:TTOO) posted its quarterly earnings results on Thursday, May, 2nd. The medical equipment provider reported ($0.34) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.04. The medical equipment provider earned $1.80 million during the quarter, compared to the consensus estimate of $1.38 million. T2 Biosystems had a negative net margin of 535.26% and a negative return on equity of 325.79%. The firm's revenue was down 21.7% on a year-over-year basis. During the same quarter last year, the company posted ($0.36) EPS. View T2 Biosystems' Earnings History.
When is T2 Biosystems' next earnings date?
What guidance has T2 Biosystems issued on next quarter's earnings?
T2 Biosystems issued an update on its second quarter 2019 earnings guidance on Thursday, May, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.8-2.1 million, compared to the consensus revenue estimate of $4.16 million.
What price target have analysts set for TTOO?
5 brokerages have issued 12 month target prices for T2 Biosystems' stock. Their predictions range from $5.00 to $10.00. On average, they expect T2 Biosystems' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 337.2% from the stock's current price. View Analyst Price Targets for T2 Biosystems.
What is the consensus analysts' recommendation for T2 Biosystems?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.
What are Wall Street analysts saying about T2 Biosystems stock?
Here are some recent quotes from research analysts about T2 Biosystems stock:
- 1. HC Wainwright analysts commented, "Our price target is derived from an estimated market value of the firm at $557M, which includes a discounted cash flow analysis based asset value of $600M for T2Dx instrument and test panels, with a 15% discount rate and 0% terminal growth rate, excluding $42M outstanding debt." (5/20/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $10 on shares of TTOO. T2 reported 1Q19 product revenue of $1.3MM (+25% y/y), beating our estimate and VisibleAlpha consensus estimates by $0.3MM. Total 1Q19 revenue beat FactSet consensus and the top-end of management’s 1Q19 revenue guide. T2 closed on 11 T2Dx contracts during the quarter, above guidance of 8-10. Management reiterated 2019 revenue guidance and provided 2Q product revenue expectations of +35% growth at the midpoint. We are positive on the momentum of T2’s start to the year, and we continue to think that 2H19 will be pivotal for consumable revenue acceleration and consequently the shares." (5/3/2019)
- 3. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (3/13/2019)
- 4. Canaccord Genuity analysts commented, "We’d like to provide our view and counter the key points made in the report: Point 1 – News of T2’s recent Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition, or that the device has value, only that it diagnoses life-threatening disease. Our response – This is true, but it’s still a positive. T2 just started its dialogue with the FDA on its T2Resistance panel, thus FDA has not reviewed data from T2. We believe that breakthrough device designation will (1) add more resources by the FDA on this device and (2) likely provide a speedier review process and ultimately FDA approval." (3/5/2019)
Has T2 Biosystems been receiving favorable news coverage?
News articles about TTOO stock have been trending somewhat positive on Monday, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. T2 Biosystems earned a coverage optimism score of 1.4 on InfoTrie's scale. They also gave media coverage about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for T2 Biosystems.
Who are some of T2 Biosystems' key competitors?
Some companies that are related to T2 Biosystems include Utah Medical Products (UTMD), Westaim (WEDXF), Pulse Biosciences (PLSE), SeaSpine (SPNE), Inovio Pharmaceuticals (INO), Iradimed (IRMD), Alphatec (ATEC), Soliton (SOLY), Apyx Medical (APYX), Neuronetics (STIM), Cytosorbents (CTSO), Liquidia Technologies (LQDA), Endologix (ELGX), RenovaCare (RCAR) and iCAD (ICAD).
What other stocks do shareholders of T2 Biosystems own?
Who are T2 Biosystems' key executives?
T2 Biosystems' management team includes the folowing people:
- Mr. John P. McDonough, CEO, Pres & Director (Age 59)
- Prof. Michael J. Cima, Co-Founder & Director (Age 59)
- Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
- Dr. Tyler E. Jacks, Co-Founder (Age 58)
- Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board
Who are T2 Biosystems' major shareholders?
T2 Biosystems' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bell Rock Capital LLC (0.77%), Gagnon Securities LLC (0.34%), Keybank National Association OH (0.15%), Focused Wealth Management Inc (0.07%), Algert Global LLC (0.06%) and Virtu Financial LLC (0.04%). Company insiders that own T2 Biosystems stock include David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.
Which major investors are selling T2 Biosystems stock?
TTOO stock was sold by a variety of institutional investors in the last quarter, including Algert Global LLC and Virtu Financial LLC. Company insiders that have sold T2 Biosystems company stock in the last year include John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Insider Buying and Selling for T2 Biosystems.
Which major investors are buying T2 Biosystems stock?
TTOO stock was purchased by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, Keybank National Association OH, Bell Rock Capital LLC, Lau Associates LLC, Focused Wealth Management Inc, Wiley BROS. Aintree Capital LLC and Cable Hill Partners LLC. View Insider Buying and Selling for T2 Biosystems.
How do I buy shares of T2 Biosystems?
Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is T2 Biosystems' stock price today?
One share of TTOO stock can currently be purchased for approximately $1.83.
How big of a company is T2 Biosystems?
T2 Biosystems has a market capitalization of $81.14 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems.
What is T2 Biosystems' official website?
How can I contact T2 Biosystems?
T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]
MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
